Fate Therapeutics
FATE
233 hedge funds and large institutions have $2.7B invested in Fate Therapeutics in 2022 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 96 increasing their positions, 70 reducing their positions, and 38 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 70
31% more call options, than puts
Call options by funds: $4.17M | Put options by funds: $3.19M
8.43% more ownership
Funds ownership: 104.93% → 113.36% (+8.4%)
7% less funds holding
Funds holding: 250 → 233 (-17)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
31% less capital invested
Capital invested by funds: $3.92B → $2.7B (-$1.23B)
34% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$101M |
| 2 |
State Street
Boston,
Massachusetts
|
+$49.6M |
| 3 |
Goldman Sachs
New York
|
+$23.7M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$20.5M |
| 5 |
AG
Artal Group
Luxembourg
|
+$16.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$35.9M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$26.7M |
| 3 |
TLP
Tri Locum Partners
New York
|
-$7.38M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.57M |
| 5 |
AWA
Artemis Wealth Advisors
New York
|
-$3.88M |
FATE Hedge Fund Activity: Q2 2022 in Review
233 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q2 2022, worth a combined $2.7B — down 31% from $3.92B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of FATE and 25 opened new positions — a net loss of 13 holders — while 70 trimmed existing stakes and 96 added.
The largest buyer was Capital World Investors, adding an estimated $101M. The largest seller was Casdin Capital, cutting an estimated $35.9M.
- 233 institutional investors held Fate Therapeutics (FATE) as of Q2 2022, down from 250 in Q1 2022.
- Funds reported $2.7B of Fate Therapeutics stock for Q2 2022, down 31% quarter-over-quarter.
- 25 funds opened new Fate Therapeutics positions in Q2 2022 and 38 closed out, a net change of -13 holders.
- The largest Fate Therapeutics buyer in Q2 2022 was Capital World Investors, an estimated $101M added.
- The largest Fate Therapeutics seller in Q2 2022 was Casdin Capital, an estimated $35.9M sold.
Based on aggregated 13F filings for Q2 2022.